ENDRA Life Sciences Inc. (NDRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NDRA Stock Price Chart Interactive Chart >
NDRA Price/Volume Stats
|Current price||$4.01||52-week high||$13.00|
|Prev. close||$4.02||52-week low||$3.16|
|Day high||$4.18||Avg. volume||13,521|
|50-day MA||$4.25||Dividend yield||N/A|
|200-day MA||$5.10||Market Cap||12.67M|
ENDRA Life Sciences Inc. (NDRA) Company Bio
ENDRA Life Sciences Inc. operates as a biotechnology company. The Company develops a medical imaging technology based on the thermoacoustic effect that improves the sensitivity and specificity of clinical ultrasound. ENDRA Life Sciences serves customers worldwide.
Most Popular Stories View All
NDRA Latest News Stream
|Loading, please wait...|
NDRA Latest Social Stream
View Full NDRA Social Stream
Latest NDRA News From Around the Web
Below are the latest news stories about ENDRA LIFE SCIENCES INC that investors may wish to consider to help them evaluate NDRA as an investment opportunity.
Gainers: Harpoon HARP +99%.Aptevo APVO +60%.ENDRA Life Sciences (NDRA) +34%.China Jo-Jo Drugstores CJJD +34%.BioVie BIVI +19%.Losers: Ambrx Biopharma AMAM -39%.Affimed…
After losing some value lately, a hammer chart pattern has been formed for ENDRA Life Sciences Inc. (NDRA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
As of Monday, ENDRA Life Sciences Inc.’s (NASDAQ:NDRA) stock closed at $0.17, down from $0.20 the previous day. While ENDRA Life Sciences Inc. has underperformed by -12.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NDRA fell by -78.01%, with highs and lows ranging from $0.93 […]
ANN ARBOR, Mich., December 05, 2022--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it will be effecting a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 63,174,455 shares to approximately 3,158,723 shares, subject to adjustment for the rounding up of fractional shar
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on ENDRA Life Sciences (NDRA - Research Report), with a price target of $5.00. The company's shares closed yesterday at $0.22.According to TipRanks, Bernardino is a 5-star analyst with an average return of 19.7% and a 32.72% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Phio Pharmaceuticals, Gamida Cell, and Geron.ENDRA Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
NDRA Price Returns